News
)
4 April 2025
Natalia Elizalde Shares Key Insights on Lentiviral Vector Advancements at Advanced Therapies London
Following her participation in Advanced Therapies London, our Chief Business Development Officer’s insights on the evolution of lentiviral vectors were featured in Drug Discovery...
Read more)
31 March 2025
VIVEbiotech celebrates 10 years of innovation in lentiviral vector manufacturing
A decade of growth, achievements, and a promising future ahead.
Read more)
24 March 2025
VIVEbiotech leads the SMART-VLPs project of the Iniciativa Transmisiones 2023
The initiative, funded by the CDTI and the Ministry of Science and Innovation, promotes innovation in lentiviral vectors through artificial intelligence and DNA biotechnology.
Read more)
18 March 2025
VIVEbiotech presents research at Bioprocessing Summit Europe
Technological Innovation researcher Ane Arrasate showcases lentiviral vector manufacturing advancements.
Read more)
18 March 2025
VIVEbiotech at Advanced Therapies 2025: connect with our team in London
Meet Natalia Elizalde, our dedicated representative, and explore how we can support your advanced therapies programs.
Read more)
13 March 2025
VIVEbiotech to Participate in Two Major International Conferences Next Week
Meet Our Experts at Advanced Therapies and Bioprocessing Summit Europe.
Read more)
28 February 2025
VIVEbiotech joins the global movement for Rare Disease Day
Supporting research, raising awareness, and bringing joy to pediatric patients.
Read more)
14 February 2025
Insights from Advanced Therapies Week 2025
Evolving Landscape of Cell and Gene Therapy (CGT) Manufacturing: Key Takeaways from Natalia Elizalde.
Read more)
11 February 2025
Celebrating women in science: honoring talent and innovation at VIVEbiotech
On the International Day of Women and Girls in Science, we recognize the invaluable contributions of women in advancing science.
Read more)
4 February 2025
VIVEbiotech joins the fight on World Cancer Day
Supporting Patients, Families, and Groundbreaking Therapies in the Battle Against Cancer.
Read more